Omnicell (NASDAQ:OMCL) Price Target Raised to $44.00

Omnicell (NASDAQ:OMCL) had its price objective boosted by equities research analysts at JPMorgan Chase & Co. from $37.00 to $44.00 in a research note issued on Thursday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 3.36% from the company’s current price.

Other analysts have also issued reports about the stock. Bank of America restated a “neutral” rating and set a $57.00 target price (up from $44.00) on shares of Omnicell in a research report on Thursday, October 31st. Benchmark reissued a “buy” rating and set a $48.00 price objective on shares of Omnicell in a research report on Wednesday, October 9th. Barclays raised their target price on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. StockNews.com lowered Omnicell from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, Craig Hallum upped their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Five research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Hold” and a consensus price target of $52.00.

Omnicell Trading Up 1.8 %

OMCL stock traded up $0.75 during trading on Thursday, reaching $42.57. The stock had a trading volume of 72,236 shares, compared to its average volume of 533,205. The stock’s 50 day moving average is $44.19 and its two-hundred day moving average is $37.20. The firm has a market cap of $1.97 billion, a PE ratio of -109.69, a PEG ratio of 35.67 and a beta of 0.81. Omnicell has a 52 week low of $25.12 and a 52 week high of $55.74.

Hedge Funds Weigh In On Omnicell

Hedge funds have recently modified their holdings of the stock. Nisa Investment Advisors LLC increased its holdings in Omnicell by 248.8% in the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock valued at $38,000 after acquiring an additional 1,000 shares during the last quarter. GAMMA Investing LLC grew its holdings in Omnicell by 78.4% during the 3rd quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after buying an additional 553 shares in the last quarter. EntryPoint Capital LLC increased its stake in Omnicell by 121.2% in the 1st quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock worth $72,000 after acquiring an additional 1,345 shares during the last quarter. CWM LLC boosted its position in shares of Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock valued at $83,000 after acquiring an additional 1,236 shares during the last quarter. Finally, 1620 Investment Advisors Inc. grew its holdings in shares of Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.